

# Tildrakizumab shows promising efficacy and safety in psoriatic arthritis

June 14 2019

---

The results of a phase 2B study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate superior efficacy and comparable safety of tildrakizumab versus placebo in patients with psoriatic arthritis.

By week 24 in the study, a significantly higher proportion of [patients](#) receiving tildrakizumab (at any [dose](#)) achieved a 90% reduction in Psoriasis Area and Severity Index (PASI 90), and a 50% reduction in American College of Rheumatology response criteria (ACR 50) versus placebo. There were four active treatment groups in which patients received 20mg, 100mg or 200mg tildrakizumab every 12 weeks, or 200mg every four weeks. The response rates improved with increasing dose however the shortening of dosing interval of 200mg from 12 to four weeks did not result in a measurable increase in skin or joint response scores. In patients receiving 200mg tildrakizumab every 12 weeks, 79.6% and 50% achieved PASI 75 and PASI 90 respectively versus 16.7% and 7.1% in the [placebo group](#) (p

Citation: Tildrakizumab shows promising efficacy and safety in psoriatic arthritis (2019, June 14) retrieved 25 April 2024 from <https://medicalxpress.com/news/2019-06-tildrakizumab-efficacy-safety-psoriatic-arthritis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.